Reports
Sale
North America Biosimulation Market Size, Trends, Growth: By Product: Software, Services, Others; By Delivery Model: Subscription Model, Ownership Model, Others; By Application: Drug Development, Drug Discovery, Others; By End User: Pharmaceutical and Biotechnology Companies, Others; Regional Analysis; Supplier Landscape; 2024-2032
North America Biosimulation Market Outlook
The global biosimulation market size was valued at USD 3.5 billion in 2023, with North America holding a substantial market share. The market is driven by technological advancements in the biosimulation software. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.
Key Takeaways
- With over 2 million new cases of cancer projected to occur in the United States in 2024, biosimulation stands as a promising approach to accelerate oncology drug development and tackle the rising burden of the disease.
- In December 2024, Certara, Inc. acquired Applied BioMath to industrialize quantitative systems pharmacology (QSP) biosimulation methods. Increased merger and acquisition initiatives among the key market players are expected to make biosimulation software more accessible and augment the North America biosimulation market share in the forecast period.
- The market is witnessing increased biosimulation applications in the drug development process. In January 2023, Cellworks announced the launch of two business units that will employ its in-house biosimulation and computational biosimulation model (CBM) to streamline clinical trials and save time and money in drug development processes.
North America Biosimulation Market Analysis
Biosimulation is a robust tool that can simulate complex biological systems, allowing researchers to predict drug behavior, reduce time and costs associated with drug development, and optimize treatment strategies. In North America, biosimulation services and software are increasingly employed for disease modeling, risk assessment of pharmaceutical products, and toxicology, among others. The expansion of biosimulation applications in various domains is likely to boost the North America biosimulation market growth in the coming years.
According to the American Cancer Society, over 2 million new cases of cancer are projected to occur in the United States in 2024. Moreover, cancer would be responsible for more than 611,000 deaths in the region in 2024. Biosimulation can predict long-term outcomes of therapies for chronic diseases including cancer, thus, it stands as a promising approach to accelerate oncology drug development and tackle the rising burden of the disease. Consequently, the market share for biosimulation systems is expected to rise in the forecast period.
One of the major North America biosimulation market trends is the increased merger and acquisition initiatives among the key market players. In December 2024, Certara, Inc. (a United States-based biotechnology company specializing in biosimulation software and technology) acquired Applied BioMath (a leading developer of mathematical modeling and biosimulation platforms in the United States) to industrialize quantitative systems pharmacology (QSP) biosimulation methods by sharing scientific and computational expertise from the companies’ existing biosimulation and artificial intelligence portfolios. This acquisition will allow the combined teams to make QSP biosimulation approach, which can predict biomarkers, endpoints, and optimal dosing regimens, more accessible and available across the industry. The rising access to such biosimulation platforms that can lead to safer drug development is expected to elevate the market value in the forecast period.
North America biosimulation market demand is driven by advancements in computational power and software capabilities that are resulting in accurate biosimulation and accelerated drug development timelines. Such advancements are encouraging leading biosimulation companies to expand their business domains and customer base. In January 2023, Cellworks, a life sciences technology company in the United States, announced the launch of two business units that will employ its in-house biosimulation and computational biosimulation model (CBM) to streamline clinical trials and save time along with money in the drug development processes. Thus, the new business will be focusing on silico approaches to test potential precision oncology drugs and deliver the new therapies to patients faster. This also indicates a rising utilization of biosimulation methods in the drug development process, which is likely to fuel market growth in North America.
North America Biosimulation Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product | Software, Services, Others |
| Delivery Model | Subscription Model, Ownership Model, Others |
| Application | Drug Development, Drug Discovery, Others |
| End User | Pharmaceutical and Biotechnology Companies, Contract Research Organization, Academic and Research Institutes |
| Country | United States of America, Canada |
North America Biosimulation Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Dassault Systems
- VeriSIM Life
- Certara Inc
- Genedata AG
- SimBioSys
- Physiomics PlC
- INOSIM Software Gmbh
- Schrodinger Inc.
- Simulation Plus Inc.
- Cadence Design Systems, Inc (OpenEye Scientific)
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Delivery Model |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Biosimulation Market Overview
3.1 North America Biosimulation Market Historical Value (2017-2023)
3.2 North America Biosimulation Market Forecast Value (2024-2032)
4 North America Biosimulation Market Landscape*
4.1 North America Biosimulation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Biosimulation: Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Delivery Model
5 North America Biosimulation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Biosimulation Market Segmentation (2017-2032)
6.1 North America Biosimulation Market (2017-2032) by Product
6.1.1 Market Overview
6.1.2 Software
6.1.3 Services
6.1.4 Others
6.2 North America Biosimulation Market (2017-2032) by Delivery Model
6.2.1 Market Overview
6.2.2 Subscription Model
6.2.3 Ownership Model
6.2.4 Others
6.3 North America Biosimulation Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Drug Development
6.3.3 Drug Discovery
6.3.4 Others
6.4 North America Biosimulation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Pharmaceutical and Biotechnology Companies
6.4.3 Contract Research Organization
6.4.4 Academic and Research Institutes
6.4.5 Others
6.5 North America Biosimulation Market (2017-2032) by Countries
6.5.1 Market Overview
6.5.2 United States of America
6.5.3 Canada
7 United States of America Biosimulation Market (2017-2032)
7.1 United states of America Biosimulation Market (2017-2032) by Product
7.1.1 Market Overview
7.1.2 Software
7.1.3 Services
7.1.4 Others
7.2 United States of America Biosimulation Market (2017-2032) by Delivery Model
7.2.1 Market Overview
7.2.2 Subscription Model
7.2.3 Ownership Model
7.2.4 Others
7.3 United States of America Biosimulation Market (2017-2032) by Application
7.3.1 Market Overview
7.3.2 Drug Development
7.3.3 Drug Discovery
7.3.4 Others
7.4 United States of America Biosimulation Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Pharmaceutical and Biotechnology Companies
7.4.3 Contract Research Organization
7.4.4 Academic and Research Institutes
7.4.5 Others
8 Canada Biosimulation Market (2017-2032)
8.1 Canada Biosimulation Market (2017-2032) by Product
8.1.1 Market Overview
8.1.2 Software
8.1.3 Services
8.1.4 Others
8.2 Canada Biosimulation Market (2017-2032) by Delivery Model
8.2.1 Market Overview
8.2.2 Subscription Model
8.2.3 Ownership Model
8.2.4 Others
8.3 Canada Biosimulation Market (2017-2032) by Application
8.3.1 Market Overview
8.3.2 Drug Development
8.3.3 Drug Discovery
8.3.4 Others
8.4 Canada Biosimulation Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Pharmaceutical and Biotechnology Companies
8.4.3 Contract Research Organization
8.4.4 Academic and Research Institutes
8.4.5 Others
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Dassault Systems
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 VeriSIM Life
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Certara Inc
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Genedata AG
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 SimBioSys
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Physiomics PlC
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 INOSIM Software Gmbh
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Schrodinger Inc.
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Simulation Plus Inc.
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Cadence Design Systems, Inc (OpenEye Scientific)
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Biosimulation Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The North America biosimulation market is expected to be driven by the rising demand for the global biosimulation market, which is anticipated to grow at a CAGR of 16.90% during the forecast period of 2024-2032 and is likely to reach a market value of USD 14.1 billion by 2032.
The growing prevalence of chronic diseases along with the rising healthcare expenditure in the region are fuelling the demand for the market.
One of the significant trends in the market is the increased merger and acquisition initiatives among the key market players. In December 2024, Certara, Inc. acquired Applied BioMath to industrialize quantitative systems pharmacology (QSP) biosimulation methods.
Based on the product, the market is segmented into software and services, among others.
By delivery model, the market is divided into subscription model and ownership model, among others.
End users of the market are pharmaceutical and biotechnology companies, contract research organizations, along with academic and research institutes, among others.
Major application areas of biosimulation include drug development and drug discovery, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Dassault Systems, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PlC, INOSIM Software Gmbh, Schrodinger Inc., Simulation Plus Inc., and Cadence Design Systems Inc. (OpenEye Scientific).
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER